We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protocol for Women at Increased Risk of Developing Breast Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00291135
First Posted: February 13, 2006
Last Update Posted: June 15, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Novartis
Information provided by (Responsible Party):
Carol Fabian, MD, University of Kansas Medical Center Research Institute
Results First Submitted: June 24, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Prevention
Condition: Breast Cancer
Intervention: Drug: letrozole

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Letrozole Letrozole, 2.5 mg daily for six months

Participant Flow:   Overall Study
    Letrozole
STARTED   42 
COMPLETED   42 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Letrozole Letrozole, 2.5 mg daily for six months

Baseline Measures
   Letrozole 
Overall Participants Analyzed 
[Units: Participants]
 42 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   40 
>=65 years   2 
Age 
[Units: Years]
Mean (Standard Deviation)
 50  (7) 
Gender 
[Units: Participants]
 
Female   42 
Male   0 
Region of Enrollment 
[Units: Participants]
 
United States   42 


  Outcome Measures

1.  Primary:   Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration.   [ Time Frame: Baseline, 6 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Carol J. Fabian, M.D.
Organization: University of Kansas Medical Center Research Institute
phone: 913-588-7791
e-mail: cfabian@kumc.edu


Publications of Results:
Other Publications:

Responsible Party: Carol Fabian, MD, University of Kansas Medical Center Research Institute
ClinicalTrials.gov Identifier: NCT00291135     History of Changes
Other Study ID Numbers: 8884
First Submitted: February 10, 2006
First Posted: February 13, 2006
Results First Submitted: June 24, 2013
Results First Posted: February 7, 2014
Last Update Posted: June 15, 2016